Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hodgkin Disease

ClinicalTrials.gov lists 1,300 trials for Hodgkin Disease or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 79.

MeSH D006689 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 308 Phase 1/2 Phase 1/2 142 Phase 2 Phase 2 442 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 89 Phase 4 Phase 4 8 Not applicable Not applicable 139 Observational Observational 160 Phase 1 Phase 1 308 Phase 1/2 Phase 1/2 142 Phase 2 Phase 2 442 Phase 2/3 Phase 2/3 6 Phase 3 Phase 3 89 Phase 4 Phase 4 8 Not applicable Not applicable 139 Observational Observational 160

Trials per phase (log scale)

2 more sections with rows

1,300 of the 1,300 trials are tagged with Hodgkin Disease itself; the rest are tagged with a narrower condition beneath it.

Get the Hodgkin Disease report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hodgkin Disease trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 73

1990: 2 trials (Not applicable 1, Phase 2 1) 1991: 1 trials (Phase 2 1) 1992: 5 trials (Phase 3 1, Phase 2 3, Phase 1 1) 1993: 4 trials (Phase 3 1, Phase 2 3) 1994: 5 trials (Observational 1, Phase 3 1, Phase 2 1, Phase 1 2) 1995: 9 trials (Observational 1, Phase 3 1, Phase 2 3, Phase 1/2 2, Phase 1 2) 1996: 13 trials (Observational 2, Phase 3 1, Phase 2 4, Phase 1 6) 1997: 24 trials (Observational 1, Not applicable 1, Phase 3 5, Phase 2 5, Phase 1/2 3, Phase 1 9) 1998: 28 trials (Not applicable 4, Phase 4 1, Phase 3 4, Phase 2 9, Phase 1/2 1, Phase 1 9) 1999: 46 trials (Observational 1, Not applicable 5, Phase 3 6, Phase 2 12, Phase 1/2 5, Phase 1 17) 2000: 41 trials (Observational 1, Not applicable 4, Phase 4 1, Phase 3 7, Phase 2 13, Phase 1/2 5, Phase 1 10) 2001: 32 trials (Observational 4, Not applicable 4, Phase 3 4, Phase 2 13, Phase 1/2 2, Phase 1 5) 2002: 32 trials (Observational 1, Not applicable 6, Phase 3 5, Phase 2 8, Phase 1/2 2, Phase 1 10) 2003: 36 trials (Not applicable 5, Phase 3 3, Phase 2/3 2, Phase 2 11, Phase 1/2 7, Phase 1 8) 2004: 42 trials (Observational 6, Not applicable 8, Phase 2 15, Phase 1/2 4, Phase 1 9) 2005: 57 trials (Observational 5, Not applicable 7, Phase 3 1, Phase 2 25, Phase 1/2 7, Phase 1 12) 2006: 49 trials (Observational 4, Not applicable 6, Phase 3 5, Phase 2 20, Phase 1/2 3, Phase 1 11) 2007: 59 trials (Other 1, Observational 6, Not applicable 10, Phase 3 4, Phase 2/3 1, Phase 2 15, Phase 1/2 9, Phase 1 13) 2008: 73 trials (Observational 16, Not applicable 5, Phase 3 8, Phase 2/3 1, Phase 2 20, Phase 1/2 7, Phase 1 16) 2009: 65 trials (Other 1, Observational 12, Not applicable 4, Phase 4 1, Phase 3 6, Phase 2 23, Phase 1/2 5, Phase 1 13) 2010: 64 trials (Observational 8, Not applicable 8, Phase 3 4, Phase 2 27, Phase 1/2 5, Phase 1 12) 2011: 58 trials (Observational 11, Not applicable 4, Phase 3 2, Phase 2 22, Phase 1/2 6, Phase 1 13) 2012: 49 trials (Observational 3, Not applicable 4, Phase 3 3, Phase 2 18, Phase 1/2 7, Phase 1 14) 2013: 47 trials (Observational 5, Not applicable 2, Phase 3 2, Phase 2 14, Phase 1/2 9, Phase 1 15) 2014: 38 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 3 2, Phase 2 7, Phase 1/2 9, Phase 1 10) 2015: 38 trials (Observational 4, Not applicable 2, Phase 2 18, Phase 1/2 6, Phase 1 8) 2016: 42 trials (Observational 5, Not applicable 3, Phase 3 2, Phase 2 13, Phase 1/2 5, Phase 1 14) 2017: 46 trials (Observational 3, Not applicable 3, Phase 3 3, Phase 2 21, Phase 1/2 7, Phase 1 9) 2018: 42 trials (Observational 7, Not applicable 1, Phase 4 1, Phase 2 18, Phase 1/2 6, Phase 1 9) 2019: 39 trials (Observational 4, Not applicable 4, Phase 3 1, Phase 2/3 1, Phase 2 14, Phase 1/2 3, Phase 1 12) 2020: 27 trials (Observational 6, Not applicable 3, Phase 3 2, Phase 2 8, Phase 1/2 1, Phase 1 7) 2021: 32 trials (Observational 10, Not applicable 6, Phase 2 12, Phase 1/2 2, Phase 1 2) 2022: 38 trials (Observational 8, Not applicable 6, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 7) 2023: 23 trials (Observational 7, Not applicable 4, Phase 3 1, Phase 2 8, Phase 1/2 2, Phase 1 1) 2024: 38 trials (Observational 8, Not applicable 6, Phase 4 2, Phase 2 9, Phase 1/2 5, Phase 1 8) 2025: 19 trials (Observational 3, Not applicable 2, Phase 2 8, Phase 1/2 1, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 19
2025 19
2024 38
2023 23
2022 38
2021 32
2020 27
2019 39
2018 42
2017 46

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 23 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 82 trials still running at the 2026-10-09 snapshot; registered median of 47 months across 967 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hodgkin Disease trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 308
Phase 1/2 142
Phase 2 442
Phase 2/3 6
Phase 3 89
Phase 4 8
Not applicable 139
Observational 160
Expanded access 5
Unknown 1

How many Hodgkin Disease trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 13
Recruiting 100
Enrolling by invitation 2
Active, not recruiting 69
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hodgkin Disease trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 79
Seagen Inc. 16

Which drugs are being tested for Hodgkin Disease? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 175
Melphalan 74
Busulfan 70

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 141
Peripheral blood stem cell transplantation 100
Etoposid 99
Mofetil Mycophenolate 90
Total Body Irradiation 77

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hodgkin Disease trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Neutrophils decreased 606 1
Febrile neutropenia 546 93
Lymphopenia 525 6
Leukocytes decreased 368 1
Death 300 32

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hodgkin Disease? (635)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood advances 2026 Yes
Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers. European journal of haematology 2026 Yes
Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. The Cochrane database of systematic reviews 2025 Yes
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study. Blood advances 2025 Yes
Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network. Radiology. Artificial intelligence 2025 Yes

Showing 5 of 635 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (15)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Hodgkin lymphoma Annual incidence 1-9 / 100 000 United States US Exact
Hodgkin lymphoma Annual incidence 1-9 / 100 000 United States US Unspecified
Hodgkin lymphoma Annual incidence 1-9 / 100 000 United States US Exact
Hodgkin lymphoma Annual incidence 1-9 / 100 000 Europe Not stated Unspecified
Hodgkin lymphoma Annual incidence 1-9 / 1 000 000 China Not stated Exact

Showing 5 of 15 prevalence observations.

Start your 14-day trial Email me all 15 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Hodgkin lymphoma 98293 Exact Orphadata Science knowledge files, Product 1
Hodgkin lymphoma 98293 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages